1 2 3 4 5 6 7 8 9 10 11 12
äàëåå Brit. J. Haematol.—1996.—Vol. 94.—P. 685-693. 13. Cross N.C.P., Feng L., Chase A. et al. Competitive PCR to estimate the number of BCR-ABL transcripts in chronic myeloid leukaemia patients after bone marrow transplantation//Blood.-1993.—Vol. 82.—P. 1929-1936. 14. Diverio D., Pandolfi P.P., Biondi A. et al. Absence of RT-PCR detectable residual disease in patients with acute promyelocytic leukemia in long-term remission // lbid.-1993.-Vol, 82,-P. 3556-3559. 15. Engel H., Drach J., Keyhani A. et al. Quantitation of minima] residual disease in acute myelogenous leukemia and myeloidysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells // Leukemia.-1999.-Vol. 13.-P. 568-577. 16. Facon Ò. Minimal residual disease detection by interphase FISH in multiple myeloma: does complete remission exist? // 27 Congress Int. Soc. Haematol. and 3 Congress Europ. Haematol. Association.—Amsterdam, 1998.—N 1556. 17. Feuring-Buske M. Persistent chromosomal abnormalities in hematopoietic stem cells of AML patients in complete remission // Abstr. Amer. Soc. Hematol. 38th Annual Meeting.—Orlando, 1996.—N 2233. 18. Galoin S., Al Saati Ò., Schlaifer D. et al. Oligonucleoti-de clonospecific probes directed against the junctional sequence t(14;18): a new tool for the assessment of minimal residual disease in follicular lymphoma // Brit. J. Haematol.-1996.-Vol. 94.-P. 676-684, 19. Gribben J.G. Detection of residual lymphoma cells by PCR in PB is significantly less predictive for relapse than detection in BM // Leukemia.-1994.-Vol. 8.— P. 3800-3807. 20. Gribben J.G. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma // New Engl. J. Med.— 1991.—Vol. 325.—P. 1525-1533. 21. Gruhn Â., Hongeng S., Yi H. et al. MRD after intensive induction therapy in childhood ALL predicts outcome // Leukemia.-1998.-Vol. 12.—P. 675-681. 22. Karzrock R., Estrov Z., Kantarjian H., Talpaz M. Conversion of interferon-induced long-term cytogenetic remissions in chronic myelogenous leukemia to PCR negativity //J. Clin. Oncol,—1998.—Vol. 16.—P. 1526-1531. 23. Laczica Ê., Novak M., Hilgarth B. et al. Competitive CBF(/MYH11 RT-PCR for quantitative of MRD during postremission therapy in acute myeloid leukemia with inversion (16): a pilot study // lbid.-1998.-Vol. 16.— P.1519-1526. 24. Marthn Ñ. Absence of detectable PML-RAR (fusion transcripts in long term remission patients after BMT for acute promyelocytic leukemia // Abstr. Amer. Soc. Hematol. 38th Annual Meeting.—Orlando, 1996.—N 1451. 25. Mitterbauer M., Brugger S., Neumeister P. et al. Clinical and molecular disease eradication after allogeneic stem cell transplantation in patients with advanced nonHodgkin's lymphoma // Abstr. Amer. Soc. Hematol., 41sh Annual Meeting.—New-Orlean, 1999.—N 4949. 26. Moos M., Schuiz R., Martin S. et al. The remission status before and PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factor äàëåå ...